AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
A phase 1/2 trial of AB-3028 in prostate cancer, run by Arsenal Biosciences, Inc., active and no longer recruiting.
Overview
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) is a phase 1/2 interventional study registered as NCT07285694 by Arsenal Biosciences, Inc., with 190 participants enrolled, started 2026-01-09 and due to reach its primary completion in 2029-05. Interventions recorded: AB-3028.
Similar pages
not linked directly; found by shared links- TrialAB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
Shares Arsenal Biosciences and the tag pipeline.
- TrialPharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms
Shares Prostate cancer and the tag pipeline.
- TrialBiodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
Shares Prostate cancer and the tag pipeline.
- TrialPSMA-PET to Guide Prostatectomy
Shares Prostate cancer and the tag pipeline.
- TrialA Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
Shares Prostate cancer and the tag pipeline.
- TrialSafety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients
Shares Prostate cancer and the tag pipeline.
- TrialPhase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).
Shares Prostate cancer and the tag pipeline.
- TrialPhase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
Shares Prostate cancer and the tag pipeline.